Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [30]
In the citing paper
“Virally transformed human cells that eliminate p53 and/or pRB function can escape crisis at very low frequencies, and invariably adopt telomere-maintenance programs: 80-90% of human tumors possess some telomerase activity, while the remainder maintain telomeres via a recombination-mediated process termed ALT (for Alternative Lengthening of Telomeres)37-40.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [39]
In the citing paper
“A significant number of human tumours can also maintain telomeres by recombination-based ALT mechanisms in the absence of telomerase 72 .”
From The common biology of cancer and ageing (2007) · cites this paper as [72]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Self-citationTelomere loss: mitotic clock or genetic time bomb?
Harley, C. B. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90018-7 · Cited by 1,139
An alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942
Telomerase activity in human ovarian carcinoma.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2900 · Cited by 677
Cited by
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
“or to invention of alternative mechanisms that can solve the telomere proble”
BackgroundMammalian Telomeres End in a Large Duplex Loop
Griffith, J. D., Comeau, L., Rosenfield, S., Stansel, R. M., Bianchi, A., Moss, H., & de Lange, T. (1999) · Cell · doi:10.1016/s0092-8674(00)80760-6 · Cited by 2,447
“…Rockefeller University at human chromosome ends, either by telomeraseNew York, New York 10021 (Bodnar et al., 1998) or an alternative mechanism (ALT; Bryan et al., 1997), is essential for long-term replicative survival of cells in vitro, and a telomerase-deficientSummary mouse strain displays…”
BackgroundThe hallmarks of cancer: A long non-coding RNA point of view
Gutschner, T., & Diederichs, S. (2012) · RNA Biology · doi:10.4161/rna.20481 · Cited by 1,802
How Shelterin Protects Mammalian Telomeres
Palm, W., & de Lange, T. (2008) · Annual Review of Genetics · doi:10.1146/annurev.genet.41.110306.130350 · Cited by 1,802
“Telomeres of polytene chromosomes in a ciliated protozoan terminate in duplex DNA loops.”
BackgroundInfluentialWhole-genome landscapes of major melanoma subtypes
Hayward, N. K., Wilmott, J. S., Waddell, N., Johansson, P. A., Field, M. A., Nones, K., Patch, A.-M., Kakavand, H., Alexandrov, L. B., Burke, H., et al. (2017) · Nature · doi:10.1038/nature22071 · Cited by 1,461
“Finally, we show the highly prevalent TERT promoter mutations in melanoma must confer selective advantage via dysregulation of telomere protection, whether via telomerase or the ALT mechanism, since they result in reduced, not increased telomere length.”
Alternative lengthening of telomeres: models, mechanisms and implications
Cesare, A. J., & Reddel, R. R. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2763 · Cited by 1,035
Self-citationAltered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., Bettegowda, C., Rodriguez, F. J., Eberhart, C. G., Hebbar, S., et al. (2011) · Science · doi:10.1126/science.1207313 · Cited by 1,083
The common biology of cancer and ageing
Finkel, T., Serrano, M., & Blasco, M. A. (2007) · Nature · doi:10.1038/nature05985 · Cited by 988
Modelling the molecular circuitry of cancer
Hahn, W. C., & Weinberg, R. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc795 · Cited by 944
Rules for Making Human Tumor Cells
Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951
Telomeres and telomerase: three decades of progress
Shay, J. W., & Wright, W. E. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0099-1 · Cited by 924
Telomere maintenance by recombination in human cells
Dunham, M. A., Neumann, A. A., Fasching, C. L., & Reddel, R. R. (2000) · Nature Genetics · doi:10.1038/82586 · Cited by 879
“Some immortalized human cell lines and some tumours maintain their telomeres in the absence of any detectable telomerase activity by a mechanism referred to as alternative lengthening of telomere”
BackgroundSelf-citationFrom polyploidy to aneuploidy, genome instability and cancer
Storchova, Z., & Pellman, D. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1276 · Cited by 810
McEachern, M. J., Krauskopf, A., & Blackburn, E. H. (2000) · Annual Review of Genetics · doi:10.1146/annurev.genet.34.1.331 · Cited by 716
Bernardo, M. E., Zaffaroni, N., Novara, F., Cometa, A. M., Avanzini, M. A., Moretta, A., Montagna, D., Maccario, R., Villa, R., Daidone, M. G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4690 · Cited by 694
“To address the possibility that alternative mechanisms of telomere maintenance, ALT ( 35 ), are operating in telomerasenegative MSCs, we screened them for the expression of associated PML bodies, which are subnuclear structures containing telomeric DNA, telomere-specific binding proteins, and proteins involved in DNA…”
BackgroundAlternative lengthening of telomeres in mammalian cells
Henson, J. D., Neumann, A. A., Yeager, T. R., & Reddel, R. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205058 · Cited by 664
“To date, clear evidence for ALT activity has only been found in abnormal situations, including human tumors, immortalized human cell lines (Table 1), and in telomerase-null mouse cell lines (Bryan et al., 1995, 1997a; Hande et al., 1999; Niida et al., 2000).”
BackgroundInfluentialSelf-citationBiology and Therapeutic Advances for Pediatric Osteosarcoma
Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 671
Yeager, T. R., Neumann, A. A., Englezou, A., Huschtscha, L. I., Noble, J. R., & Reddel, R. R. (1999) · PubMed · Cited by 845
Self-citationTelomere maintenance as a target for anticancer drug discovery
Neidle, S., & Parkinson, G. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd793 · Cited by 624
Lovejoy, C. A., Li, W., Reisenweber, S., Thongthip, S., Bruno, J., de Lange, T., De, S., Petrini, J. H. J., Sung, P. A., Jasin, M., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002772 · Cited by 629
“independent telomere maintenance pathway, referred to as ALT [1].”
BackgroundSelf-citationSystematic analysis of telomere length and somatic alterations in 31 cancer types
Barthel, F. P., Wei, W., Tang, M., Martinez-Ledesma, E., Hu, X., Amin, S. B., Akdemir, K. C., Seth, S., Song, X., Wang, Q., et al. (2017) · Nature Genetics · doi:10.1038/ng.3781 · Cited by 614
Kilian, A., Bowtell, D. D. L., Abud, H. E., Hime, G. R., Venter, D. J., Keese, P. K., Duncan, E. L., Reddel, R. R., & Jefferson, R. A. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.12.2011 · Cited by 585
“The LIM1215 and T47D cell lines are both telomerase-positive (26).”
BackgroundSelf-citationVonderheide, R. H., Hahn, W. C., Schultze, J. L., & Nadler, L. M. (1999) · Immunity · doi:10.1016/s1074-7613(00)80066-7 · Cited by 570
Connecting Chromosomes, Crisis, and Cancer
Maser, R. S., & DePinho, R. A. (2002) · Science · doi:10.1126/science.297.5581.565 · Cited by 561
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 555
“Some tumors may maintain their telomeres by an alternative mechanism, which is telomerase independent, designated as alternative lengthening of telomeres, which appears to maintain telomeres through recombination-based interchromosomal exchange of sequence information (4, 5).”
BackgroundHerbert, B.-S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., & Corey, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14276 · Cited by 539
TIN2, a new regulator of telomere length in human cells
Kim, S.-H., Kaminker, P., & Campisi, J. (1999) · Nature Genetics · doi:10.1038/70508 · Cited by 525
“17 ), and some maintain telomeres without telomerase (presumably by recombinatio”
BackgroundDNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity
Henson, J. D., Cao, Y., Huschtscha, L. I., Chang, A. C., Au, A. Y. M., Pickett, H. A., & Reddel, R. R. (2009) · Nature Biotechnology · doi:10.1038/nbt.1587 · Cited by 498
“Screening by CC assay may be useful for individuals with tumor predisposition syndromes such as Werner, Rothmund-Thomson and Li-Fraumeni, in which ALT + tumors have been foun”
MethodSelf-citationHeaphy, C. M., Subhawong, A. P., Hong, S.-M., Goggins, M. G., Montgomery, E. A., Gabrielson, E., Netto, G. J., Epstein, J. I., Lotan, T. L., Westra, W. H., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.018 · Cited by 516
“However, telomere loss may also be compensated in some cancers by the telomerase-independent telomere maintenance mechanism termed alternative lengthening of telomeres (ALT), which is thought to be dependent on homologous recombination.(10) The ALT phenotype is identified at the cellular level by the presence of ALT-a…”
BackgroundHallmarks of senescence in carcinogenesis and cancer therapy
Shay, J. W., & Roninson, I. B. (2004) · Oncogene · doi:10.1038/sj.onc.1207518 · Cited by 502
Telomere Position Effect in Human Cells
Baur, J. A., Zou, Y., Shay, J. W., & Wright, W. E. (2001) · Science · doi:10.1126/science.1062329 · Cited by 479
Gilson, E., & Géli, V. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2259 · Cited by 457
RTEL1 Dismantles T Loops and Counteracts Telomeric G4-DNA to Maintain Telomere Integrity
Vannier, J.-B., Pavicic-Kaltenbrunner, V., Petalcorin, M. I. R., Ding, H., & Boulton, S. J. (2012) · Cell · doi:10.1016/j.cell.2012.03.030 · Cited by 463
T-loops and the origin of telomeres
de Lange, T. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1359 · Cited by 461
Teng, S.-C., & Zakian, V. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.8083 · Cited by 457
“This pattern is similar to the exceptionally long telomeres in human tumors (8) or cultured cells (7) that lack telomerase.”
BackgroundResultZscan4 regulates telomere elongation and genomic stability in ES cells
Zalzman, M., Falco, G., Sharova, L. V., Nishiyama, A., Thomas, M., Lee, S.-L., Stagg, C. A., Hoang, H. G., Yang, H.-T., Indig, F. E., et al. (2010) · Nature · doi:10.1038/nature08882 · Cited by 441
The telomerase reverse transcriptase: components and regulation
Nugent, C. I., & Lundblad, V. (1998) · Genes & Development · doi:10.1101/gad.12.8.1073 · Cited by 438
“Both a substantial number of established human cell lines, as well as in vivo tumors, are telomerase-minus, but despite the lack of enzyme activity, telomeres are still exceptionally long (Kim et al. 1994; Bryan et al. 1995, 1997).”
BackgroundMultiple Tumor Suppressor Pathways Negatively Regulate Telomerase
Lin, S.-Y., & Elledge, S. J. (2003) · Cell · doi:10.1016/s0092-8674(03)00430-6 · Cited by 363
Telomerase contributes to tumorigenesis by a telomere length-independent mechanism
Stewart, S. A., Hahn, W. C., O'Connor, B. F., Banner, E. N., Lundberg, A. S., Modha, P., Mizuno, H., Brooks, M. W., Fleming, M., Zimonjic, D. B., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182407599 · Cited by 431
Roberson, R. S., Kussick, S. J., Vallieres, E., Chen, S.-Y. J., & Wu, D. Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1270 · Cited by 428
“Beyond M1, as cells further divide and telomeres shorten, a second restriction point (M2 or crisis) is encountered, at which time aberrant expression of telomerase or alternative telomeraseindependent mechanisms of telomere lengthening enables rare cells to traverse this restriction and become immortalized (12, 13).”
BackgroundTelomere dysfunction and tumour suppression: the senescence connection
Deng, Y., Chan, S. S., & Chang, S. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2393 · Cited by 411
Telomere-binding Protein TRF2 Binds to and Stimulates the Werner and Bloom Syndrome Helicases
Opresko, P. L., von Kobbe, C., Laine, J.-P., Harrigan, J., Hickson, I. D., & Bohr, V. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205396200 · Cited by 392
Le, S., Moore, J. K., Haber, J. E., & Greider, C. W. (1999) · Genetics · doi:10.1093/genetics/152.1.143 · Cited by 410
Potts, P. R., & Yu, H. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1259 · Cited by 379
Cellular senescence, cancer and aging: the telomere connection
Campisi, J., Kim, S.-H., Lim, C.-S., & Rubio, M. (2001) · Experimental Gerontology · doi:10.1016/s0531-5565(01)00160-7 · Cited by 400
van der Burgt, I., Chrzanowska, K. H., Smeets, D., & Weemaes, C. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.2.153 · Cited by 376
Clusterin/Apolipoprotein J in human aging and cancer
Trougakos, I. P., & Gonos, E. S. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00041-9 · Cited by 376
T cells and aging january 2002 update
Pawelec, G. (2002) · Frontiers in Bioscience · doi:10.2741/a831 · Cited by 369
The complex structure and dynamic evolution of human subtelomeres
Mefford, H. C., & Trask, B. J. (2002) · Nature Reviews Genetics · doi:10.1038/nrg727 · Cited by 346
Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells.
Izbicka, E., Wheelhouse, R. T., Raymond, É., Davidson, K. K., Lawrence, R. A., Sun, D., Windle, B. E., Hurley, L. H., & Hoff, D. D. V. (1999) · PubMed · Cited by 426
Pawelec, G. (1998) · Frontiers in Bioscience · doi:10.2741/a266 · Cited by 357
Telomeric DNA in ALT Cells Is Characterized by Free Telomeric Circles and Heterogeneous t-Loops
Cesare, A. J., & Griffith, J. D. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.22.9948-9957.2004 · Cited by 343
“ated promyelocytic leukemia bodies (APBs) (5, 6, 47).”
BackgroundNatural and pharmacological regulation of telomerase
Mergny, J.-L. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.4.839 · Cited by 352
Ferguson, L. R., Chen, H., Collins, A. R., Connell, M., Damia, G., Dasgupta, S., Malhotra, M., Meeker, A. K., Amedei, A., Amin, A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.005 · Cited by 336
“Whereas most cancers use telomerase to maintain telomere length, a significant minority of cancers (typically non-carcinomas) utilize ALT, a telomerase independent, homologous recombination based mechanism [46–48].”
Telomeres: Cancer to Human Aging
Stewart, S. A., & Weinberg, R. A. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104518 · Cited by 334
“As discussed above, more than 90% of all human tumors utilize telomerase for telomere maintenance, whereas the telomeraseindependent telomere maintenance (ALT) mechanism mentioned above is observed in only 7–10% of tumors (Bryan et al. 1997, Shay & Bacchetti 1997).”
BackgroundCanela, A., Vera, E., Klatt, P., & Blasco, M. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609367104 · Cited by 335
Alternative Lengthening of Telomeres Is Characterized by High Rates of Telomeric Exchange
Londoño-Vallejo, J. A., Der-Sarkissian, H., Cazes, L., Bacchetti, S., & Reddel, R. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4035 · Cited by 319
Self-citationWerner syndrome: Clinical features, pathogenesis and potential therapeutic interventions
Oshima, J., Sidorova, J. M., & Monnat, R. J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.03.002 · Cited by 304
Hodes, R. J., Hathcock, K. S., & Weng, N.-P. (2002) · Nature Reviews Immunology · doi:10.1038/nri890 · Cited by 309
A critical role for telomeres in suppressing and facilitating carcinogenesis
Artandi, S. E., & DePinho, R. A. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00047-7 · Cited by 318
Understanding TERT Promoter Mutations: A Common Path to Immortality
Bell, R. J. A., Rube, H. T., Xavier-Magalhães, A., Costa, B. M., Mancini, A., Song, J. S., & Costello, J. F. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0003 · Cited by 307
“The cancers found to be telomerase negative use an alternative mechanism of telomere lengthening termed ALT(21-23).”
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
Koelsche, C., Sahm, F., Capper, D., Reuss, D., Sturm, D., Jones, D. T. W., Kool, M., Northcott, P. A., Wiestler, B., Böhmer, K., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1195-5 · Cited by 303
Gowan, S. M., Harrison, J. R., Patterson, L., Valenti, M., Read, M. A., Neidle, S., & Kelland, L. R. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12212-2 · Cited by 303
Mathon, N. F., & Lloyd, A. C. (2001) · Nature Reviews Cancer · doi:10.1038/35106045 · Cited by 308
Integrative genomic and transcriptomic analysis of leiomyosarcoma
Chudasama, P., Mughal, S. S., Sanders, M. A., Hübschmann, D., Chung, I., Deeg, K. I., Wong, S.-H., Rabe, S., Hlevnjak, M., Zapatka, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02602-0 · Cited by 306
“The remaining 15% maintain telomere length via a telomerase-independent mechanism termed ALT, which appears to be particularly prevalent in cells of mesenchymal origin 23 – 25 .”
Henson, J. D., Hannay, J. A., McCarthy, S. W., Royds, J. A., Yeager, T. R., Robinson, R. A., Wharton, S. B., Jellinek, D. A., Arbuckle, S. M., Yoo, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.217.11.1 · Cited by 305
Self-citationClynes, D., Jelinska, C., Xella, B., Ayyub, H., Scott, C., Mitson, M., Taylor, S., Higgs, D. R., & Gibbons, R. J. (2015) · Nature Communications · doi:10.1038/ncomms8538 · Cited by 294
“However, 15% of cancers achieve immortality via an alternative, telomerase-independent mechanism (the so-called ALT pathway), which depends on homologous recombination (HR) 2,3 .”
Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation
Fehrmann, F., & Laimins, L. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206554 · Cited by 292
Molecular Pathogenesis of Osteosarcoma
Kansara, M., & Thomas, D. M. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0505 · Cited by 273
“In addition, a recent study has found that 47% of 58 osteosarcomas examined (especially in young patients) were ALT positive and correlated with tumor aggres-siveness (Henson et al ., 2005) and chromosomal instability (Scheel et al ., 2001).”
InfluentialTeng, S. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00092-7 · Cited by 271
Two Modes of Survival of Fission Yeast Without Telomerase
Nakamura, T. M., Cooper, J. P., & Cech, T. R. (1998) · Science · doi:10.1126/science.282.5388.493 · Cited by 280
Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme
Hakin-Smith, V, Jellinek, D., Levy, D., Carroll, T., Teo, M., Timperley, W., McKay, M., Reddel, R., & Royds, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12681-5 · Cited by 267
Self-citationMechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer
Leão, R., Apolónio, J. D., Lee, D., Figueiredo, A., Tabori, U., & Castelo-Branco, P. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0422-8 · Cited by 265
Johnson, F. B., Marciniak, R. A., McVey, M., Stewart, S. A., Hahn, W. C., & Guarente, L. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.905 · Cited by 269
“Rare cells survive crisis and maintain their telomeres either by expression of telomerase or by a telomerase-independent mechanism (or mechanisms) termed ALT (alternative lengthening of telomeres; Bryan et al., 1997).”
BackgroundSpontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions
Cesare, A. J., Kaul, Z., Cohen, S. B., Napier, C. E., Pickett, H. A., Neumann, A. A., & Reddel, R. R. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1725 · Cited by 263
“ALT is an MRE11-RAD50-NBS1–dependent, recombination-mediated telomere replication mechanism that results from the loss of a normal but as-yet-unknown suppressor functio”
BackgroundSelf-citationSandberg, A. A., & Bridge, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00105-5 · Cited by 262
“The ALT telomere phenotype is recognized by the presence of heterogeneous telomeres ranging from less than 3 kb to 50 kb in length, a range notably greater than the maximum length in nonneoplastic somatic tissues (∼10–15 kb in humans) [30,35].”
BackgroundInfluentialThe aging process and potential interventions to extend life expectancy.
Tosato, M., Zamboni, V., Ferrini, A., & Cesari, M. (2007) · PubMed Central · Cited by 381
Pennarun, G., Granotier, C., Gauthier, L. R., Gomez, D., Hoffschir, F., Mandine, E., Riou, J.-F., Mergny, J.-L., Mailliet, P., & Boussin, F. D. (2005) · Oncogene · doi:10.1038/sj.onc.1208468 · Cited by 241
Castelo-Branco, P., Choufani, S., Mack, S., Gallagher, D., Zhang, C., Lipman, T., Zhukova, N., Walker, E. J., Martin, D., Merino, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70110-4 · Cited by 250
Xu, D., Wang, Q., Gruber, A., Björkholm, M., Chen, Z., Zaid, A., Selivanova, G., Peterson, C., Wiman, K. G., & Pisa, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203890 · Cited by 257
“Moreover, the maintenance of telomeres by a mechanism (alternative lengthening of telomeres) other than telomerase activation has been observed in a subset of human tumors (Bryan et al., 1995, 1997).”
BackgroundStudies of the molecular mechanisms in the regulation of telomerase activity
LIU, J. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.15.2091 · Cited by 254
“mechanisms across different animal species (51).”
ALTernative Telomere Maintenance and Cancer
Dilley, R. L., & Greenberg, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.007 · Cited by 244
Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis
Hackett, J. A., & Greider, C. W. (2002) · Oncogene · doi:10.1038/sj.onc.1205061 · Cited by 246
“In these cells telomere function may be restored though the ALT pathway.”
BackgroundAssaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers
Henson, J. D., & Reddel, R. R. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.06.009 · Cited by 236
“The long heterogeneous telomere length pattern remains the best-established marker for ALT in human cells, including tumors archived under conditions where it is possible to extract high-quality genomic DNA [5,31].”
BackgroundSelf-citationCoexistence of Alternative Lengthening of Telomeres and Telomerase in hTERT-Transfected GM847 Cells
Perrem, K., Colgin, L. M., Neumann, A. A., Yeager, T. R., & Reddel, R. R. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3862-3875.2001 · Cited by 245
“GM847 untransfected 50/50 (100) 41/704 (6) GM847/hTERT-3 (PD 42) 12/50 (24) GM847/hTERT-3 (PD 106) 9/50 (18) 8/690 (1) GM847/hTERT-3 (PD 138) 13/50 (26) GM847/hTERT-6 (PD 46) 13/55 (23) GM847/hTERT-6 (PD 82) 15/50 (30) 1/894 (0.”
BackgroundSelf-citationThe telosome/shelterin complex and its functions
Xin, H., Liu, D., & Songyang, Z. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-232 · Cited by 222
“A number of human tumors and tumor cell lines have a telomeraseindependent mechanism for telomere elongation that involves homologous recombination, and which is referred to as ‘alternative lengthening of telomeres’ (ALT) [47].”
BackgroundInfluentialBreak-induced replication: A review and an example in budding yeast
Kraus, E., Leung, W.-Y., & Haber, J. E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151008198 · Cited by 233
Gowan, S. M., Heald, R., Stevens, M. F. G., & Kelland, L. R. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12507-2 · Cited by 230
Telomeres, aging and cancer: In search of a happy ending
Kim, S.-H., Kaminker, P., & Campisi, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205077 · Cited by 230
“In addition, telomerase-independent mechanisms can maintain telomeres (Bryan et al., 1997), most likely by homologous recombination (Dunham et al., 2000).”
BackgroundPaternal age is positively linked to telomere length of children
Unryn, B. M., Cook, L. S., & Riabowol, K. T. (2005) · Aging Cell · doi:10.1111/j.1474-9728.2005.00144.x · Cited by 229
Replicative Aging and Gene Expression in Long-Term Cultures of Human Bone Marrow Stromal Cells
Banfi, A., Bianchi, G., Notaro, R., Luzzatto, L., Cancedda, R., & Quarto, R. (2002) · Tissue Engineering · doi:10.1089/107632702320934001 · Cited by 226
“30 Although some immortal cell lines and some tumors maintain their telomeres by alternative mechanism, 31–33 constitutive telomerase activity has been observed in the germ line 34 and in most malignant tumors and immortalized cell lines.”
Telomere analysis by fluorescence in situ hybridization and flow cytometry
Hultdin, M., Gronlund, E., Norrback, K. F., Eriksson-Lindstrom, E., Roos, G., & Just, T. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.16.3651 · Cited by 219
Bailey, S. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh691 · Cited by 213
“However, some telomerasenegative cells escape crisis by an as yet poorly understood mechanism referred to as ‘alternative lengthening of telomeres’ (ALT) (9,10).”
BackgroundLord, R. V. N., Salonga, D., Danenberg, K. D., Peters, J. H., DeMeester, T. R., Park, J. M., Johansson, J., Skinner, K. A., Chandrasoma, P., DeMeester, S. R., et al. (2000) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(00)80049-9 · Cited by 221
PML nuclear bodies and chromatin dynamics: catch me if you can!
Corpet, A., Kleijwegt, C., Roubille, S., Juillard, F., Jacquet, K., Texier, P., & Lomonte, P. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa828 · Cited by 203
Silva, B., Pentz, R., Figueira, A. M., Arora, R., Lee, Y. W., Hodson, C., Wischnewski, H., Deans, A. J., & Azzalin, C. M. (2019) · Nature Communications · doi:10.1038/s41467-019-10179-z · Cited by 209
Eisenberg, D. T. A. (2011) · American Journal of Human Biology · doi:10.1002/ajhb.21127 · Cited by 209
“The majority of cancers overexpress telomerase (Bechter et al., 1998; Bryan et al., 1997; Kim et al., 1994).”
Devereux, T. R., Horikawa, I., Anna, C. H., Annab, L. A., Afshari, C. A., & Barrett, J. C. (1999) · PubMed · Cited by 260
The role of senescence and immortalization in carcinogenesis
Reddel, R. R. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.477 · Cited by 212
Self-citationTelomere Length Assessment in Human Archival Tissues
Meeker, A. K., Gage, W. R., Hicks, J. L., Simon, I., Coffman, J. R., Platz, E. A., March, G. E., & De Marzo, A. M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62553-9 · Cited by 209
Metadata
- Authors
- Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R.
- Affiliations
- Children's Medical Research Institute (AU)
- Corresponding author
- Reddel, Roger R.
- Venue
- Nature Medicine
- Published
- 1997-11
- Volume
- 3
- Issue
- 11
- Pages
- 1271-1274
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2013073993
- Cited by
- 1,292
- References
- 39
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 31 · 2021: 34 · 2020: 44 · 2019: 52 · 2018: 27 · 2017: 54 · 2016: 35 · 2015: 52 · 2014: 33 · 2013: 52 · 2012: 39
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- alternative lengthening of telomeres, telomere maintenance, telomerase, tumor-derived cell lines, cell immortalization, telomerase inhibitors, cancer therapy, telomere loss
- MeSH terms
- Adult, DNA Nucleotidyltransferases, Humans, Neoplasms, Tumor Cells, Cultured, Deoxyribonucleases, Type II Site-Specific, Telomere, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.